Cinctive Capital Management LP lessened its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 30.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,317 shares of the company's stock after selling 46,792 shares during the quarter. Cinctive Capital Management LP's holdings in Sanofi were worth $5,224,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Abel Hall LLC lifted its holdings in Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after buying an additional 194 shares during the period. Providence Capital Advisors LLC raised its holdings in shares of Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management grew its position in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after purchasing an additional 217 shares during the period. Bailard Inc. increased its position in Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after acquiring an additional 220 shares during the last quarter. Finally, Old Port Advisors boosted its holdings in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after buying an additional 232 shares during the last quarter. Institutional investors own 14.04% of the company's stock.
Analysts Set New Price Targets
SNY has been the subject of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $62.50.
Get Our Latest Stock Report on Sanofi
Sanofi Stock Down 4.8 %
Sanofi stock traded down $2.64 during trading on Friday, reaching $51.98. The stock had a trading volume of 3,162,438 shares, compared to its average volume of 2,289,137. The stock has a market cap of $131.92 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57. The business has a 50 day moving average price of $55.37 and a 200 day moving average price of $52.71. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, analysts predict that Sanofi will post 4.36 EPS for the current year.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Articles
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
